ROOT Loses 33% in 3 Months, Trades at a Premium: How to Play the Stock — Neutral
ROOT Zacks Investment Research — September 02, 2025ROOT shares are down 33% in three months, yet the insurer boasts strong profitability, tech-driven growth and analyst optimism.
Live Nation's Share-Price Reveals It As A Visionary, Not A Monopolist — Positive
LYV Forbes — September 02, 2025Frank Price, the former President of Columbia Pictures, died last month. While at Columbia, he “green lit” critically acclaimed hits including Tootsie, Ghostbusters, Gandhi, and Out of Africa.
Tariffs continue to be a wild card. Anxiety gripped the markets on Tuesday, pushing the price of gold past the $3,500 mark en route to a new all-time high.
Limestone Branch Distillery collaborates with Ross & Squibb Distillery on 2025 release of Yellowstone Limited Edition — Neutral
MGPI PRNewsWire — September 02, 202510th anniversary expression features a blend of three unique mash bills aged 10 years and bottled at 105 proof ST. LOUIS , Sept.
NIO Significant Growth in Struggling EV Market, TSLA Traction Slows — Positive
NIO TSLA Schwab Network — September 02, 2025Tu Le says there were plenty of bright spots in NIO Inc.'s (NIO) latest earnings, which he argues lays the groundwork for significant growth. He adds that it and Chinese competitors like BYD Co. (BYDDY) continue to push the "innovation envelope" as Tesla (TSLA) struggles to accelerate international sales.
ADBE's AI-Focus Aids Subscription Revenues: Is the Growth Sustainable? — Neutral
ADBE Zacks Investment Research — September 02, 2025Adobe's subscription revenues jump 11.5% to $5.64B, with Acrobat and Express driving user growth past 700M monthly actives.
Dan Primack, Axios business editor, joins 'The Exchange' to discuss Klarna nearing IPO as the IPO market sees a post-Labor Day push.
German software giant SAP announced Tuesday (Sept. 2) that it is investing 20 billion euros ($23.3 billion) to expand its “sovereign cloud” services as it bets on Europe's desire to keep its data within its borders.
CIMG Inc. Completes the Previously Announced Sale of $55 Million of its Common Stock for 500 Bitcoin — Neutral
IMG PRNewsWire — September 02, 2025BEIJING , Sept. 2, 2025 /PRNewswire/ -- CIMG Inc. ("CIMG" or the "Company") (Nasdaq: IMG), a business group specializing in digital health and sales development, which utilizes technology and marketing to enhance its partners' sales growth and commercial value, today announced that on September 2, 2025, it closed the previously announced sale of sale of 220 million shares of its common stock at $0.25 per share for gross proceeds of $55,000,000 in exchange for 500 Bitcoin.
Ryanair Issues Impressive Traffic Numbers for August 2025 — Positive
RYAAY Zacks Investment Research — September 02, 2025RYAAY reports an August 2025 load factor of 96%, which remained flat on a year-over-year basis and sequentially.
FI DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Fiserv, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FI — Neutral
FI GlobeNewsWire — September 02, 2025NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Fiserv, Inc. (NYSE: FI) between July 24, 2024 and July 22, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline.
Johnson Fistel Begins Investigation on Behalf of Petco Health and Wellness Company, Inc. Long-Term Shareholders — Neutral
WOOF GlobeNewsWire — September 02, 2025SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into certain board members and executive officers of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) for potential breaches of fiduciary duties and violations of the federal securities laws.
HIMS' Personalized Wellness Platform Expands Preventive Care Access — Positive
HIMS Zacks Investment Research — September 02, 2025Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.
ALAB's Robust Portfolio Aids Revenue Growth: A Sign of More Upside? — Positive
ALAB Zacks Investment Research — September 02, 2025Astera Lab benefits from a diverse portfolio and strong AI-driven demand, surging revenue growth, with Q3 sales set to climb further.
Should You Buy, Sell or Hold UiPath Stock Ahead of Q2 Earnings? — Positive
PATH Zacks Investment Research — September 02, 2025PATH Q2 performance is likely to benefit from subscription revenue growth and strong tech partnerships, though license sales remain a key drag.
PLEASANTON, Calif. , Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: Citi's 2025 Global TMT Conference, New York, NY.
Medidata Secures a Leader Position in Everest Group's PEAK Matrix® Assessment for eCOA, Driving the New Patient Experience Forward — Neutral
EG GlobeNewsWire — September 02, 2025Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard Medidata eCOA was the highest Leader recognized in the evaluation, supporting over 1M+ patients and reducing study build timeline by up to 50% compared to the industry standard
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential — Positive
CYTK Seeking Alpha — September 02, 2025MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is significant, with U.S. peak sales scenarios ranging from ~$1.2B–$3.5B (net) depending on adoption, and higher if global and non-obstructive HCM are included. Differentiation vs. Camzyos (mavacamten) lies in aficamten's shorter half-life, faster titration, and cleaner safety profile, which may drive higher physician preference despite BMS's head start.
